IMMX Share Price Performance
US$3.61
1.95 (117.47%)
Price US$3.61
Share PriceUS$3.61
Immix Biopharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
IMMX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Immix Biopharma, Inc. Key Details
About IMMX
- Founded
- 2012
- Employees
- 20
- CEO
- WebsiteView website
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
